UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 205

Sortiert nach

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?

Cancers, 2020-05, Vol.12 (6), p.1378

2020

Volltextzugriff (PDF)

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

Cancers, 2023-02, Vol.15 (5), p.1416

2023

Volltextzugriff (PDF)

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

European journal of cancer (1990), 2022-11, Vol.176, p.181-188

2022

Volltextzugriff (PDF)

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

Cancers, 2018-12, Vol.10 (12), p.506

2018

Volltextzugriff (PDF)

The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype

NPJ breast cancer, 2020, Vol.6 (1), p.8-8, Article 8

2020

Volltextzugriff (PDF)

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

Oncoimmunology, 2017-02, Vol.6 (2), p.e1253654-e1253654

2017

Volltextzugriff (PDF)

SPAG5 : the ultimate marker of proliferation in early breast cancer?

The lancet oncology, 2016-07, Vol.17 (7), p.863-865

2016

Volltextzugriff (PDF)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

Journal of translational medicine, 2023-09, Vol.21 (1), p.1-637, Article 637

2023

Volltextzugriff (PDF)

First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter

Molecular cancer therapeutics, 2022-11, Vol.21 (11), p.1742-1743

2022

Volltextzugriff (PDF)

The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers

Oncoimmunology, 2016-03, Vol.5 (3), p.e1085148-e1085148

2016

Volltextzugriff (PDF)

The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps

Cancer communications (London, England), 2023-08, Vol.43 (8), p.938-942

2023

Volltextzugriff (PDF)

PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

Oncoimmunology, 2017-03, Vol.6 (3), p.e1278100-e1278100

2017

Volltextzugriff (PDF)

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer

NPJ breast cancer, 2021-05, Vol.7 (1), p.48-48, Article 48

2021

Volltextzugriff (PDF)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response

Journal of translational medicine, 2022-10, Vol.20 (1), p.1-464, Article 464

2022

Volltextzugriff (PDF)

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer

Biochimica et biophysica acta. Reviews on cancer, 2018-04, Vol.1869 (2), p.248-255

2018

Volltextzugriff (PDF)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors

Oncoimmunology, 2021-01, Vol.10 (1), p.1929724-1929724

2021

Volltextzugriff (PDF)

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial

Frontiers in oncology, 2022-07, Vol.12, p.946257-946257

2022

Volltextzugriff (PDF)

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

Frontiers in oncology, 2020-11, Vol.10, p.575978-575978

2020

Volltextzugriff (PDF)

CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors

The American journal of surgical pathology, 2018-02, Vol.42 (2), p.150-159

2018

Volltextzugriff (PDF)

Enhancement of Breast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different Actions

Cancers, 2020-06, Vol.12 (7), p.1730

2020

Volltextzugriff (PDF)

Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis

Frontiers in oncology, 2021-03, Vol.11, p.564506-8

2021

Volltextzugriff (PDF)

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting

Cancers, 2020-10, Vol.12 (10), p.3058

2020

Volltextzugriff (PDF)

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study

Molecular oncology, 2022-05, Vol.16 (10), p.2057-2070

2022

Volltextzugriff (PDF)

Sacituzumab govitecan in triple-negative breast cancer

Annals of translational medicine, 2022-06, Vol.10 (11), p.647-647

2022

Volltextzugriff (PDF)

Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC

NPJ breast cancer, 2022-01, Vol.8 (1), p.12-12, Article 12

2022

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Aktive Filter

KollektionPublisher website

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(203)

Publikationsform

Artikel
(188)
Berichte
(16)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

SPAG5 : the ultimate marker of proliferation in early breast cancer?

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter

The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers

The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps

PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors

Enhancement of Breast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different Actions

Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study

Sacituzumab govitecan in triple-negative breast cancer

Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC

Aktive Filter

Suchergebnisse filtern